Septerna Doses First Participants in SEP-479 Clinical Trial
Septerna announced the dosing of the first participants in its Phase 1 clinical trial of SEP-479, its oral small molecule PTH1R agonist being developed for the treatment of patients with hypoparathyroidism. The Phase 1 clinical trial is a single-ascending dose and multiple-ascending dose clinical trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SEP-479 in healthy adult volunteers. The randomized, placebo-controlled Phase 1 clinical trial is expected to enroll up to 150 healthy adult participants.
